Piper Sandler Upgrades Supernus Pharmaceuticals (SUPN) to Overweight
Tweet Send to a Friend
Piper Sandler analyst David Amsellem upgraded Supernus Pharmaceuticals (NASDAQ: SUPN) from Neutral to Overweight with a price target of $65.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
